Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Thursday 28 January, 2021

Omega Diagnostics Gp

Exercise of Options and Total Voting Rights

RNS Number : 2496N
Omega Diagnostics Group PLC
28 January 2021


28 January 2021



("Omega" or the "Company" or the "Group")


Exercise of Options and Total Voting Rights



Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 16,666   new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options under the Company's Third Unapproved Share Option scheme by certain option holders.

Application has been made to the London Stock Exchange for the 16,666   new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2021.


After Admission, the total number of Ordinary Shares in issue will be 180,017,154 and the total number of voting rights will therefore be 180,017,154. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.


The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.




Omega Diagnostics Group PLC 

Tel: 01259 763 030

Colin King, Chief Executive

Kieron Harbinson, Group Finance Director

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t